1. Skin Cancer Research Report SWAG SSG Maxine Taylor Senior Research Delivery Manager
17/05/2016

2. Clinical Research Network: West of England
Prof Hugh Barr: Cancer Divisional Clinical Lead
National and local engagement for whole cancer portfolio
Dr Christopher Herbert: Skin Cancer Specialty Lead
Represents WE at national skin CSG annual meeting
Local engagement with clinicians regarding network wide approach to skin cancer portfolio and recruitment
Maxine Taylor: Senior Research Delivery Manager
Local oversight of cancer portfolio and performance
Linking in with all networks and national teams
Richard Munday: Cancer Portfolio Facilitator
Preparation of reports on behalf of local teams and specialty leads
Circulation of new studies
Expert re EDGE database, ODP database

3. National cancer research objectives
Every network to deliver a portfolio of studies that include ‘challenging’ studies in support of national cancer priorities:
Cancer surgery: 4 recruits per 100,000 population
Radiotherapy: 6 recruits per 100,000
Rare cancers: 12 recruits per 100,000
Children: 3 per 100,000
16-25 age group: collect baseline information

4. This year’s portfolio Short Name
Gloucestershire Hospitals NHS Foundation Trust
NORTH BRISTOL NHS TRUST
UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST
Grand Total
CANC Nivolumab for Subjects with Histologically Confirmed Stage III or Stage IV Melanoma 1
CANC Nivolumab and/or Ipilimumab in Melanoma
MelMarT - Melanoma Margins Trial - Pilot Study
NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma
NCRN492 NEMO - MEK162 vs dazcarbazine in advanced NRAS melanoma
EORTC E18081 –adjuvant PEG-Interferon x 2 years vs surveillance after resection of higher risk ulcerated and node negative melanomas 4 5

5. EORTC studies open
1325
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group
1208
Minitub: Prospective registry on Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissections (CLND) or Nodal Observation.
18081
Adjuvant peginterferon alpha-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group

6. EORTC study in set up SPECTAmel: Screening Patients with melanoma tumors for Efficient Clinical Trial Access
Trial Status
Regulatory in process
Dates
Date of activation:
Data management at EORTC
Full
Phase
Randomized trial
Type -
Targeted Sample size
EORTC Groups: - - All Groups: 700
Number of steps 1
Drug
Study Staff
Caroline Robert Study Coordinator - Gustave Roussy, Villejuif Stefan Suciu Statistician - EORTC Headquarters, Brussels Sandrine Marreaud Coordinating Physician - EORTC Headquarters, Brussels Aline Gheeraert Project Manager - EORTC Headquarters, Brussels aline.gheeraert (at) eortc.be
Type of cancer
Melanoma  Uveal Melanoma 
Participating Groups
EORTC Melanoma Group(Coordinating Group)
Protocol summary
ClinicalTrials.gov
NCT number
NCT
EudraCT

7. Contact & reference details